Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Beavis

Showing results (41-50 of 92) with videos related to

Pageof 10
Sort By:
Oncoimmunology|January 4, 2018
T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's LymphomaTamara Hilmenyuk, Carla A Ruckstuhl, Michael Hayoz, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2013
Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumorsPaul A Beavis, Upulie Divisekera, Christophe Paget, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 11, 2020
Efficient CRISPR/Cas9 Gene Editing in Uncultured Naive Mouse T Cells for In Vivo StudiesSimone Nüssing, Imran G House, Conor J Kearney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2013
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cellsLiza B John, Christel Devaud, Connie P M Duong, et al.
Frontiers in Pharmacology|July 18, 2024
Pharmacologic inhibition of dipeptidyl peptidase 1 (cathepsin C) does not block <i>in vitro</i> granzyme-mediated target cell killing by CD8 T or NK cellsVivien R Sutton, Sally V Watt, Hedieh Akhlaghi, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|November 4, 2025
Implantable drug delivery system improves tolerability of anti-CD40/anti-PD1 and chemotherapy in a murine model of breast cancerSamantha J Wade, Elahe Minaei, Ashleigh Hope, et al.
Clinical & Translational Immunology|November 27, 2019
Tissue-specific tumor microenvironments influence responses to immunotherapiesAmanda J Oliver, Ashleigh S Davey, Simon P Keam, et al.
Clinical Epigenetics|July 28, 2022
Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancerSimon J Hogg, Olga Motorna, Conor J Kearney, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 15, 2018
Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicityA J Davenport, R S Cross, K A Watson, et al.
Cancer Discovery|November 19, 2021
PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor ImmunityFlorian Wiede, Kun-Hui Lu, Xin Du, et al.
Pageof 10

Showing results (41-50 of 92) with videos related to

Sort By:
Pageof 10
Oncoimmunology|January 4, 2018
T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's LymphomaTamara Hilmenyuk, Carla A Ruckstuhl, Michael Hayoz, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2013
Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumorsPaul A Beavis, Upulie Divisekera, Christophe Paget, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 11, 2020
Efficient CRISPR/Cas9 Gene Editing in Uncultured Naive Mouse T Cells for In Vivo StudiesSimone Nüssing, Imran G House, Conor J Kearney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2013
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cellsLiza B John, Christel Devaud, Connie P M Duong, et al.
Frontiers in Pharmacology|July 18, 2024
Pharmacologic inhibition of dipeptidyl peptidase 1 (cathepsin C) does not block <i>in vitro</i> granzyme-mediated target cell killing by CD8 T or NK cellsVivien R Sutton, Sally V Watt, Hedieh Akhlaghi, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|November 4, 2025
Implantable drug delivery system improves tolerability of anti-CD40/anti-PD1 and chemotherapy in a murine model of breast cancerSamantha J Wade, Elahe Minaei, Ashleigh Hope, et al.
Clinical & Translational Immunology|November 27, 2019
Tissue-specific tumor microenvironments influence responses to immunotherapiesAmanda J Oliver, Ashleigh S Davey, Simon P Keam, et al.
Clinical Epigenetics|July 28, 2022
Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancerSimon J Hogg, Olga Motorna, Conor J Kearney, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 15, 2018
Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicityA J Davenport, R S Cross, K A Watson, et al.
Cancer Discovery|November 19, 2021
PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor ImmunityFlorian Wiede, Kun-Hui Lu, Xin Du, et al.
Pageof 10